Tadalafil (Generic) and Pregabalin Interaction: What Patients and Clinicians Need to Know

Tadalafil is metabolized by CYP3A4; pregabalin is eliminated renally and does not inhibit or induce CYP enzymes, so pregabalin does not raise or lower tadalafil blood levels. The interaction that matters is pharmacodynamic: both drugs can independently cause dizziness, drowsiness, and blood pressure lowering, and taking them together can add those effects rather than multiply plasma drug exposure. This is described in the individual FDA prescribing information for each drug, not in a dedicated interaction study of the pair. The practical decision for a patient or prescriber is not "can these be combined" but "does this specific patient's age, kidney function, and pregabalin dose make the additive risk worth a closer look."

What each drug does, in plain terms

Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor FDA-approved for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It works by blocking the enzyme that breaks down cyclic GMP in vascular smooth muscle, which relaxes blood vessels and lowers vascular resistance. This is why tadalafil, like other PDE5 inhibitors, has a mild blood-pressure-lowering effect even at therapeutic doses.

Pregabalin is a gabapentinoid (an alpha-2-delta calcium channel ligand) approved for neuropathic pain, fibromyalgia, and as adjunctive epilepsy therapy, and used off-label in some anxiety presentations. It reduces release of excitatory neurotransmitters in the central nervous system. Its labeled adverse effects include dizziness and somnolence that occur in a meaningful share of patients in the manufacturer's clinical trials, and these effects are dose-related. Pregabalin also has a modest central sympatholytic action that can contribute to blood pressure lowering and peripheral edema, particularly in older adults.

The FDA prescribing information for each drug is the primary source for these mechanism and labeled-effect statements:

• Tadalafil label: current FDA prescribing information for tadalafil (available via FDA's Drugs@FDA database)
• Pregabalin label: current FDA prescribing information for pregabalin (available via FDA's Drugs@FDA database)

These are the manufacturer labels on file with the FDA; exact numeric figures for blood pressure change or adverse event incidence should be pulled directly from the current label text during medical review rather than assumed from a prior draft, since label versions are updated over time.

Is this a pharmacokinetic or pharmacodynamic interaction?

This is a pharmacodynamic interaction, not a pharmacokinetic one, and that distinction changes how it should be managed.

Tadalafil is metabolized primarily by hepatic CYP3A4. Pregabalin is eliminated largely unchanged by the kidneys and, at labeled therapeutic concentrations, does not inhibit or induce major CYP enzymes. Because of that, pregabalin is not expected to raise or lower tadalafil blood levels through a metabolic pathway, and standard drug-interaction references reflect this by not flagging a CYP-based mechanism for this pair.

The mechanism that does matter is additive effect: both drugs, independently, can cause dizziness, drowsiness, and drops in blood pressure, particularly on standing. When both are on board, a patient who has mild dizziness on tadalafil alone and mild drowsiness on pregabalin alone may notice more pronounced lightheadedness than either drug produces on its own, especially when standing up quickly or after a hot shower, when the body's own vasodilation is already near its peak.

How is this interaction typically classified, and what does that mean?

Commercial drug-interaction checkers (the kind pharmacists and prescribers commonly use) generally classify this pairing as a moderate interaction: not something that rules out co-prescribing, but something that should be flagged and discussed rather than ignored.

In practice, a moderate pharmacodynamic classification means:

1. The combination can still make clinical sense for many patients.
2. The prescriber should be aware of the additive-effect risk and document that awareness.
3. The patient should receive specific counseling before starting both agents together, not generic "take as directed" instructions.
4. A follow-up check on tolerability, ideally within a few weeks of starting or changing either dose, is reasonable.

Who is most likely to notice the additive effect

Some patient profiles carry a higher chance of a noticeable interaction:

Older adults. Aging reduces the body's ability to compensate for sudden blood pressure changes on standing (baroreflex sensitivity declines with age). Geriatric prescribing guidance generally flags both PDE5 inhibitors and gabapentinoids as classes associated with fall risk in older adults, which is a reason to pay closer attention when both are used together in this population. The exact guideline language and citation should be confirmed against the current edition before publication.

Patients on higher-dose pregabalin. Dizziness and somnolence are dose-related for pregabalin; patients on 300 mg per day or more are more likely to report these effects than patients on 75-150 mg per day.

Patients with reduced kidney function. Pregabalin clearance tracks kidney function closely, so reduced creatinine clearance raises pregabalin blood levels at a given dose, which in turn raises the chance of CNS and blood-pressure effects. Tadalafil dosing also requires adjustment in significant renal impairment per its label. The NIDDK provides general background on chronic kidney disease and its effect on drug handling: niddk.nih.gov. Specific dose-cap numbers for pregabalin by creatinine clearance band should come directly from the current pregabalin label rather than a secondary summary, and are a matter for prescriber judgment, not a substitute for individualized dosing decisions.

Patients who drink alcohol. The tadalafil label warns that alcohol and tadalafil are both mild vasodilators and that combining mild vasodilators can increase blood-pressure-lowering effects. Pregabalin's label similarly notes additive cognitive and motor effects with other CNS depressants, historically described in combination with agents such as opioids or benzodiazepines. Adding alcohol on top of tadalafil and pregabalin together is a reasonable thing to counsel against, even though no dedicated three-way study exists.

Patients on other blood-pressure-lowering or sedating medicines. Antihypertensives, opioids, benzodiazepines, and muscle relaxants each add their own contribution to the same additive-effect risk.

What is established, what is plausible, and what is not known

This is the honest evidence boundary for this specific drug pair, distinct from what is known about each drug individually.

Established from FDA labeling: Tadalafil lowers blood pressure modestly on its own and its label warns about additive effects with other vasodilators, including alcohol. Pregabalin causes dose-related dizziness and somnolence and its label warns about additive CNS effects with other CNS depressants. Pregabalin is renally eliminated and is not a CYP3A4 substrate, inhibitor, or inducer.

Plausible but not directly tested: That combining tadalafil and pregabalin produces additive dizziness, sedation, and orthostatic blood pressure lowering greater than either drug alone. This follows logically from each drug's independent, labeled pharmacology, and is consistent with how drug-interaction databases classify pharmacodynamically similar combinations generally. It has not been confirmed in a dedicated trial of this specific pair.

Not established: There is no published, dedicated pharmacokinetic or pharmacodynamic drug-drug interaction trial of tadalafil combined with pregabalin. Statements about how large the combined effect is in real patients, including any specific number of adverse event reports in pharmacovigilance databases, would require direct verification against a current database query rather than being asserted as a fixed figure. Readers and clinicians who want that data point should query the FDA Adverse Event Reporting System (FAERS) directly: fda.gov FAERS dashboard.

Neither drug's FDA label names the other by drug name as a specific interaction. The concern here is inferred from class-level pharmacodynamics, which is the standard way pharmacists and prescribers handle plausible-but-untested combinations that share a mechanism of harm.

Evidence-status interaction assessment

Use this table to separate what can be stated with confidence from what still needs verification before it is relied on in patient counseling or a chart note.

A practical framework for counseling and follow-up

This is a general framework, not individualized dosing or diagnostic advice. Actual dose decisions belong to the prescriber managing the patient.

Before starting the second drug, it is reasonable to check sitting and standing blood pressure, ask about current alcohol use, ask about any fall history in the past year (especially for patients over 60), and review the full medication list for other blood-pressure-lowering or sedating drugs.

Counseling points worth stating explicitly include rising slowly from sitting or lying positions, being cautious about alcohol on days tadalafil is taken, not driving until the combined effect on alertness is known, and reporting dizziness, near-fainting, or falls promptly.

Follow-up within a few weeks of starting or changing either drug, focused specifically on orthostatic symptoms and sedation, is a reasonable general practice; it does not necessarily require an in-person visit.

If problems appear, the choice of which drug to adjust first is a clinical judgment call that should weigh the reason each drug is being used. Interrupting pregabalin abruptly is a specific concern in patients using it for seizure control, since stopping it can carry seizure risk, which is a reason some clinicians reduce the vasodilator (tadalafil) dose before touching pregabalin, though this is a general consideration rather than a fixed rule.

Special populations that deserve extra caution

Reduced kidney function. Because pregabalin clearance depends on kidney function and tadalafil exposure also rises as kidney function declines, patients with meaningfully reduced creatinine clearance can end up with higher effective exposure to both drugs at label-standard doses. This is a reason renal function is checked before and during treatment with either drug, and it is a reasonable trigger to treat the combination with more caution than in a patient with normal kidney function. Specific dose-cap numbers should be taken from the current FDA labels rather than repeated from memory.

Liver impairment. Tadalafil is hepatically metabolized and its label restricts or discourages use in more severe liver impairment; pregabalin is not meaningfully affected by liver disease. This means liver impairment selectively raises the tadalafil side of the equation.

Older adults. Slower drug clearance in general is a reason to start at the lower end of the labeled dose range for each drug and to titrate cautiously when both are used together, consistent with general geriatric prescribing caution rather than a fixed numeric adjustment specific to this pair.

When to seek urgent care

A patient who develops fainting, a fall with injury, chest pain, significant shortness of breath, or an erection lasting more than four hours needs urgent medical evaluation rather than a routine follow-up call. Severe or persistent lightheadedness on standing, especially in an older adult or someone with reduced kidney function, is also worth an urgent call to the prescribing clinician rather than waiting for a scheduled visit.

Key takeaway

The tadalafil-pregabalin combination is not a metabolism-based drug interaction; it is an additive-effect concern involving two drugs that each independently cause dizziness, sedation, and blood pressure lowering. It is not contraindicated, and for many patients the combination is used without incident, but the risk is not uniform. It rises with pregabalin dose, age, reduced kidney function, alcohol use, and the presence of other sedating or blood-pressure-lowering medicines. No dedicated trial has tested this exact pair, so the guidance here is built from each drug's individual labeling and general pharmacodynamic reasoning rather than direct interaction data, and that limitation should be part of how this information is used in practice.